Gastrodia elata in neurological disorders: a systematic review of anti-inflammatory mechanisms and cross-disease therapeutic potential
- 1Beijing University of Chinese Medicine, Beijing, China
- 2Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 3Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China
Abstract
BackgroundNeuroinflammation serves as a common pathological substrate across various neurological disorders, including neurodegenerative diseases, cerebrovascular diseases, and neuroimmune conditions. Key pathogenic mechanisms underlying these disorders include aberrant microglial activation, sustained release of pro-inflammatory cytokines, and dysregulation of critical signaling cascades, particularly the NLRP3 inflammasome, NF-κB, and Nrf2/HO-1 pathways, all of which collectively contribute to progressive neuronal damage and functional decline.ObjectivesThis review aims to systematically evaluate the preclinical evidence for the neuroprotective effects of Gastrodia elata Blume and its major bioactive constituents—gastrodin, parishin, p-hydroxybenzyl alcohol, and G. elata polysaccharides—in the treatment of Parkinson’s disease, Alzheimer’s disease, acute ischemic stroke, vascular dementia, and epilepsy, with a particular focus on their modulation of inflammation-related signaling pathways.MethodsA comprehensive literature search was performed in PubMed, Web of Science, ScienceDirect, China National Knowledge Infrastructure (CNKI), and Wanfang databases from inception to May 2026. Original studies investigating G. elata or its components in animal or cellular models of the aforementioned diseases and reporting inflammatory mechanisms were included.ResultsG. elata and its active constituents regulate multiple neuroinflammation-associated signaling pathways, including Nrf2/HO-1, NF-κB/NLRP3, JAK2/STAT3, and MAPK, thereby suppressing inflammatory responses. Mechanistically, these effects are primarily manifested as: (1) inhibition of microglial M1 polarization and consequent reduction of pro-inflammatory cytokine release; (2) blockade of inflammation-induced neuronal death through suppression of ferroptosis, pyroptosis, and apoptosis; (3) enhancement of Nrf2 nuclear translocation, leading to upregulation of antioxidant enzymes and attenuation of oxidative stress-mediated inflammation (e.g., ROS-driven cascades); and (4) modulation of the gut microbiota–brain axis to reduce both peripheral and central low-grade chronic inflammation.ConclusionDespite certain limitations in the existing evidence, this review clearly identifies future research priorities, including investigation of non-gastrodin active components, causal validation using gene-knockout models, and development of brain-targeted delivery strategies. These findings provide a valuable reference for the mechanism-guided development of neuroprotective agents derived from G. elata.
Related
- Microbiome-Immune Crosstalk in Inflammatory Skin Diseases: Mechanisms and Therapeutic Potential of Probiotics.
- The role of adipokines in the inflammatory theory of depression: mechanisms and therapeutic applications.
- The therapeutic landscape of cannabidiol: a systematic review of molecular mechanisms, clinical efficacy in oncology and neurology, and regulatory changes.
- Transient Post-infectious Multisystem Inflammatory Overlap Presentation in a Pediatric Patient With Neurological, Hepatic, Gastrointestinal, and Autoimmune Manifestations: A Rare Case From Azerbaijan
- Vitamin D–VDR Signaling Across Thyroid Disorders: A Systematic Review of Molecular Mechanisms, Autoimmunity, Genetic Susceptibility, Experimental Evidence and Therapeutic Translation
BibTeX
@article{chu2026gastrodia,
title = {{Gastrodia elata in neurological disorders: a systematic review of anti-inflammatory mechanisms and cross-disease therapeutic potential}},
author = {Yi-yu Chu and Bo-yu Wang and Cai-yan Qu and Yu Lan and Li-ye Wang and Meng Mao},
journal = {Frontiers in Aging Neuroscience},
year = {2026},
month = oct,
doi = {10.3389/fnagi.2026.1967946},
url = {https://doi.org/10.3389/fnagi.2026.1967946},
note = {CC BY},
}
RIS
TY - JOUR
TI - Gastrodia elata in neurological disorders: a systematic review of anti-inflammatory mechanisms and cross-disease therapeutic potential
AU - Yi-yu Chu
AU - Bo-yu Wang
AU - Cai-yan Qu
AU - Yu Lan
AU - Li-ye Wang
AU - Meng Mao
PY - 2026
DA - 2026/10/26
JO - Frontiers in Aging Neuroscience
DO - 10.3389/fnagi.2026.1967946
UR - https://doi.org/10.3389/fnagi.2026.1967946
AB - BackgroundNeuroinflammation serves as a common pathological substrate across various neurological disorders, including neurodegenerative diseases, cerebrovascular diseases, and neuroimmune conditions. Key pathogenic mechanisms underlying these disorders include aberrant microglial activation, sustained release of pro-inflammatory cytokines, and dysregulation of critical signaling cascades, particularly the NLRP3 inflammasome, NF-κB, and Nrf2/HO-1 pathways, all of which collectively contribute to progressive neuronal damage and functional decline.ObjectivesThis review aims to systematically evaluate the preclinical evidence for the neuroprotective effects of Gastrodia elata Blume and its major bioactive constituents—gastrodin, parishin, p-hydroxybenzyl alcohol, and G. elata polysaccharides—in the treatment of Parkinson’s disease, Alzheimer’s disease, acute ischemic stroke, vascular dementia, and epilepsy, with a particular focus on their modulation of inflammation-related signaling pathways.MethodsA comprehensive literature search was performed in PubMed, Web of Science, ScienceDirect, China National Knowledge Infrastructure (CNKI), and Wanfang databases from inception to May 2026. Original studies investigating G. elata or its components in animal or cellular models of the aforementioned diseases and reporting inflammatory mechanisms were included.ResultsG. elata and its active constituents regulate multiple neuroinflammation-associated signaling pathways, including Nrf2/HO-1, NF-κB/NLRP3, JAK2/STAT3, and MAPK, thereby suppressing inflammatory responses. Mechanistically, these effects are primarily manifested as: (1) inhibition of microglial M1 polarization and consequent reduction of pro-inflammatory cytokine release; (2) blockade of inflammation-induced neuronal death through suppression of ferroptosis, pyroptosis, and apoptosis; (3) enhancement of Nrf2 nuclear translocation, leading to upregulation of antioxidant enzymes and attenuation of oxidative stress-mediated inflammation (e.g., ROS-driven cascades); and (4) modulation of the gut microbiota–brain axis to reduce both peripheral and central low-grade chronic inflammation.ConclusionDespite certain limitations in the existing evidence, this review clearly identifies future research priorities, including investigation of non-gastrodin active components, causal validation using gene-knockout models, and development of brain-targeted delivery strategies. These findings provide a valuable reference for the mechanism-guided development of neuroprotective agents derived from G. elata.
SN - 1663-4365
ER -